Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
PAREXEL International Reports First Quarter Fiscal Year 2017 Results and Announces New Share Repurchase Program
October 26, 2016 4:02 PM EDTFirst Quarter Fiscal Year 2017 Results (compared to First Quarter Fiscal Year 2016)
GAAP diluted earnings per share of $0.75, up 66.7%; adjusted earnings per share of $0.76, up 8.6% Service revenue of $500.9 million, down 2.2%; constant currency revenue decline of 2.4% Gross new business of $930 million Company guides to GAAP EPS of $3.55-$3.89 and adjusted EPS of $3.71-$4.05 for Fiscal Year 2017 Board approved new $200 million share repurchase programBOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) today reported... More
BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
October 25, 2016 8:30 AM EDTReport ranks PRA Health Sciences and INC Research as the most active CROs
NEW YORK--(BUSINESS WIRE)-- BioPharm Insight (BPI), the most comprehensive life science market intelligence and analytics solution, today released its exclusive... More
